Treatment with light benefits Alzheimer’s patients, Wayne State University finds

 

Detroit, Michigan (January 11, 2012) – Exposure to light appears to have therapeutic effects on Alzheimer’s disease patients, a Wayne State University researcher has found. In a study published recently in the Western Journal of Nursing Research, LuAnn Nowak Etcher, Ph.D., assistant professor of nursing, reported that patients treated with blue-green light were perceived by their caregivers as having improved global functioning.

 

Caregivers said patients receiving the treatment seemed more awake and alert, were more verbally competent and showed improved recognition, recollection and motor coordination. They also said patients seemed to recapture their personalities and were more engaged with their environment. Patients’ moods also were described as improved.

 

Etcher’s work is inspired by her interest in a phenomenon known as "sundowning," when Alzheimer’s patients sleep during the day, wake up later and may be up all night long. Part of her doctoral research was to utilize light, a common intervention for circadian disorders, to regulate the rest-activity patterns of women with Alzheimer’s.

 

This study, Etcher said, was an effort to address disagreement among researchers on the effect of therapeutic light in regulating rest-activity patterns in Alzheimer’s patients. The study involved 20 women older than age 65 with Alzheimer’s dementia from nursing homes in southeast Michigan. Each patient was assigned randomly to an experimental group receiving blue-green light treatments or a control group receiving dim red light.

 

A commercially available visor used to treat seasonal affective disorder and jet lag was used to administer the light to patients. Caregivers — patients’ family members and nursing facility personnel — were not told which type of light was hypothesized to have physiologic effects.

 

Although blue-green light recipients comprised the active experimental group, Etcher said she was surprised when some recipients of red light — the placebo group — also were reported as showing improvements, with caregivers saying their patients were calmer and had reduced resistance to care.

 

The level of effects varied, Etcher said, noting that while the blue-green group recipients were largely reported by caregivers as showing improvement, a few showed little to no effect from the treatments.

 

"Some of the rest-activity pattern disruptions that we see associated with Alzheimer’s dementia may not necessarily be circadian based," Etcher said. "They may be due to unmet needs, pain or other phenomena, and therefore would not respond to an intervention aimed at regulation of the circadian system."

 

Calling her study preliminary, she said it now needs to be replicated with a larger sample and different demographics.

 

In addition to ascertaining which behaviors are circadian based, establishing which methods are most appropriate to analyze data like Etcher’s requires exploration, she said. She is proposing further work that uses two different nonlinear analytic methods to examine sensitivity and specificity to detect change in circadian patterns, with a long-term goal of developing interventions to regulate those patterns to the benefit of patients’ overall function.

 

"If they sleep better at night, and are more awake during the day, they can eat, they can interact with other people and they can take advantage of other cueing agents in the environment," she said. "In addition to light during daytime and darkness during the nighttime, smells at mealtimes, food intake, interactions — all these things in conjunction help regulate our day."

 

 

Wayne State University is one of the nation’s pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://www.research.wayne.edu.

 


 

Wayne State University, 11.01.2012 (tB)

MEDICAL NEWS

Fitness watches generate useful information, but increase patient anxiety
A new device provides added protection against COVID-19 during endoscopic…
81 million Americans lacking space or bathrooms to follow COVID…
Front-line physicians stressed and anxious at work and home
EULAR: High-Dose Glucocorticoids and IL-6 Receptor inhibition can reduce COVID-19…

SCHMERZ PAINCARE

Morbus Fabry mittels Datenanalysen aus dem PraxisRegister Schmerz aufspüren
Neandertaler besaßen niedrigere Schmerzschwelle
Deutscher Schmerz- und Palliativtag 2020 – ONLINE
Deutsche Gesellschaft für Schmerzmedizin fordert Anerkennung von Nicht-Psychologen in der…
DBfK: Besondere Rolle für Pflegeexpert/innen Schmerz – nicht nur in…

DIABETES

“Körperstolz”: Michael Krauser managt seinen Diabetes digital
Der richtige Sensor – von Anfang an
Diabetes mellitus: Ein Risikofaktor für frühe Darmkrebserkrankungen
Fastenmonat Ramadan: Alte und neue Herausforderung für chronisch Erkrankte während…
Sanofi setzt sich für die Bedürfnisse von Menschen mit Diabetes…

ERNÄHRUNG

Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…
Fast Food, Bio-Lebensmittel, Energydrinks: neue Daten zum Ernährungsverhalten in Deutschland
Neue Daten zur Ernährungssituation in deutschen Krankenhäusern und Pflegeheimen: Mangelernährung…
Baxter: Parenterale Ernährung von Patienten mit hohem Aminosäurenbedarf

ONKOLOGIE

Darolutamid bei Prostatakarzinom: Hinweis auf beträchtlichen Zusatznutzen
Multiples Myelom: Wissenschaftler überprüfen den Stellenwert der Blutstammzelltransplantation
Neues zur onkologischen Supportiv- und Misteltherapie und aktuelle Kongress-Highlights zum…
Finanzierung der ambulanten Krebsberatung weiterhin nicht gesichert
Lungenkrebsscreening mittels Low-Dose-CT

MULTIPLE SKLEROSE

Geschützt: Multiple Sklerose: Novartis’ Siponimod verzögert Krankheitsprogression und Hirnatrophie bei…
Neurofilamente als Diagnose- und Prognosemarker für Multiple Sklerose
Bedeutung der Langzeittherapie bei Multipler Sklerose – mehr Sicherheit und…
Bristol Myers Squibb erhält Zulassung der Europäischen Kommission für Ozanimod…
Einige MS-Medikamente könnten vor SARS-CoV-2/COVID-19 schützen

PARKINSON

Neue Studie zur tiefen Hirnstimulation bei Parkinson-Erkrankung als Meilenstein der…
Putzfimmel im Gehirn
Parkinson-Patienten in der Coronakrise: Versorgungssituation und ein neuer Ratgeber
Neuer Test: Frühzeitige Differenzialdiagose der Parkinson-Erkrankung
Gegen das Zittern: Parkinson- und essentiellen Tremor mit Ultraschall behandeln…